Project Grant R61AG090275
Award Date
12/1/24
Completion Date
11/30/26
Dollars Obligated
$704K
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Lebanon, NH 03756, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $604,627 to the Trustees of Dartmouth College to conduct research aimed at deconvoluting the heterogeneity of chimeric antigen receptor (CAR) T cells in order to engineer durable antitumor immunity. The research project, which runs from January 1, 2025 to December 31, 2029, will use dynamic lineage recording to understand how individual CAR T cell subsets behave in vivo and...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $728,370 to The Washington University to develop engineered T cell approaches for Alzheimer's disease. The goal is to design and develop "CARDINAL" (CAR Disease Interventions for Alzheimer's) T cells that are programmed to expand and persist at the site of Alzheimer's pathology, and release neuroprotective payloads such as IL-4 and BDNF to support neuronal function and improve...
This Project Grant award of $734,778 from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) will support the development of a novel, scalable, allogeneic cell platform based on human induced pluripotent stem cell (iPSC)-derived chimeric antigen receptor (CAR) macrophages. The primary goals are to evaluate CAR designs for targeting pathogenic tau protein and to incorporate genetic modifications to mitigate inflammatory responses, in order to address both...
The National Institute on Aging (NIA) awarded a $810,596 Project Grant under the Aging Research program (CFDA 93.866) to New York University (NYU) to develop a novel chimeric antigen receptor (CAR) macrophage (MI) therapy for Alzheimer's disease (AD). The objectives are to create "off-the-shelf" human induced pluripotent stem cell-derived MIs that can be genetically programmed to target and clear amyloid-beta deposits, a key pathological hallmark of AD. The 2-year award period runs...
This federal Project Grant award from the National Institute on Aging's (NIA) Aging Research Program (CFDA 93.866) provides $834,627 to the University of Florida to develop a novel "theranostic" (therapeutic and diagnostic) chimeric antigen receptor (CAR) T cell platform for targeting senescent cells associated with Alzheimer's disease and related dementias. The key products to be delivered include: A senescence-responsive theranostic abscisic acid (ABA) inducer that can selectively...
This federal Project Grant award from the National Institute on Aging (NIA), under CFDA Program 93.866 Aging Research, provides $613,571 to the University of Chicago to develop an in vivo gene therapy approach for treating Alzheimer's disease. The project aims to engineer chimeric antigen receptor (CAR)-expressing microglia that can recognize and clear amyloid-beta plaques, a key pathological hallmark of Alzheimer's. The researchers will package mRNA encoding anti-amyloid-beta CAR constructs and...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $374,000.00 to the University of California, Los Angeles (UCLA) to develop and evaluate a novel hematopoietic stem cell-based chimeric antigen receptor (CAR) macrophage therapy for Alzheimer's disease (AD). The key objectives are to: 1) Optimize an AB-targeting CAR-macrophage (CAR-M) therapy for in vitro efficacy against AB aggregates and reducing neuroinflammation, and 2) Investigate the safety...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $442,024 to Trustees of Dartmouth College to conduct research on the cellular mechanisms driving antibody effector functions. The research aims to elucidate the complex relationships between antigens, antibodies, and effector cells in order to establish design criteria for engineering antibody therapeutics with predictable and robust effector...
This $338,527 Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) supports research to understand the role of inhibitory interneurons in the pathophysiology of Alzheimer's disease (AD) and related dementias (ADRD). The key objectives are to: 1) Identify disrupted interneuron gene expression in post-mortem AD brain tissue, 2) Characterize inhibitory dysfunction in AD-derived induced interneurons in vitro, and 3) Assess the impact of transplanting healthy...
This $3,931,590 Project Grant awarded by the National Institute on Aging (under CFDA 93.866 - Aging Research) aims to investigate the mechanisms by which nasal administration of anti-CD3 antibodies can have a neuroprotective effect in Alzheimer's disease (AD) mouse models. The grant supports research at Brigham & Women's Hospital Inc. (a subsidiary of Partners Healthcare System Incorporated) to: 1) examine how nasal anti-CD3 modulates microglia and astrocytes in the 3xTG AD mouse model,...